Conference Dates

June 12 – 17, 2022


Scale-up of suspension mammalian or insect cells to large bioreactors is commonly done in industry. However, some developers choose to scale-out adherent systems to produce desired components, since adherent systems are more challenging and costly to scale-up than suspension systems. Serum is often required for adherent cell culture, which can introduce lot-to-lot variability to the production process, can be cost-prohibitive, and raises ethical concerns. Additionally, increased global demand for serum is threatening to cause supply chain issues, which can impact manufacturing at scale. A process which reduces the concentration of serum while eliminating the challenges of scale-up for adherent systems would be extremely desirable to the biopharmaceutical industry. We have conducted scale-up studies using adherent human diploid MRC-5 fibroblast cells cultured with microcarriers with our serum reduced medium (SRM). The Diploid SRM System, is a three-component product with base medium and two supplement formulations optimized for cell growth and virus production, respectively.

Please click Download on the upper right corner to see the full abstract.